Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q4 FY25 results · Jan–Mar 2025

Sun Pharmaceutical Industries reported revenue from operations of ₹12,958.84 crore (up 8.1% from Q4 FY24) and net profit of ₹2,153.93 crore (down 19.0% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY25	Q4 FY24	YoY	Q3 FY25	QoQ
Revenue from operations	12,958.84	11,982.90	+8.1%	13,675.46	−5.2%
Other income	612.87	605.94	+1.1%	465.62	+31.6%
Total income	13,571.71	12,588.84	+7.8%	14,141.08	−4.0%
Profit before share of associates & JVs and tax	3,254.35	2,815.52	+15.6%	3,476.40	−6.4%
Share of profit/(loss) of associates & JVs	(6.71)	(7.85)		(4.56)
Net profit for the period	2,153.93	2,658.74	−19.0%	2,912.98	−26.1%
Attributable to shareholders of the company	2,149.88	2,654.58	−19.0%	2,903.38	−26.0%
EPS, basic (₹)	9.00	11.10	−18.9%	12.10	−25.6%
Net margin (%)	16.6	22.2		21.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY25	Q4 FY24	YoY	Q3 FY25	QoQ
Revenue from operations	7,185.74	5,639.14	+27.4%	6,191.81	+16.1%
Other income	132.00	118.88	+11.0%	68.39	+93.0%
Total income	7,317.74	5,758.02	+27.1%	6,260.20	+16.9%
Profit before tax	2,612.08	1,401.78	+86.3%	1,264.93	+106.5%
Net profit for the period	2,000.46	867.60	+130.6%	1,181.05	+69.4%
EPS, basic (₹)	8.30	3.60	+130.6%	4.90	not comparable
Net margin (%)	27.8	15.4		19.1

Consolidated

Filed with BSE: 22 May 2025, 20:06 IST
Board meeting: 22 May 2025
Period: 01 Jan 2025 to 31 Mar 2025
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 22 May 2025, 20:06 IST
Board meeting: 22 May 2025
Period: 01 Jan 2025 to 31 Mar 2025
Review status: Audited
Source: XBRL filing on BSE